We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00347802
First Posted: July 4, 2006
Last Update Posted: June 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Innovative Medical
  Purpose
To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.

Condition Intervention Phase
Glaucoma Drug: Bimatoprost 0.03%, Travoprost 0.004% Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Official Title: Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Naive to treatment or washed off any ocular hypotensive agents
    • Untreated IOP >19 mm Hg
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete study

Exclusion Criteria:

  • · Known contraindication to bimatoprost or travoprost, or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study
    • History of intraocular surgery within the last 3 months
    • Prior discontinuation of any of the study medications for reasons related to efficacy or safety
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00347802


Locations
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Robert Noecker, MD UPMC Eye Center
  More Information

ClinicalTrials.gov Identifier: NCT00347802     History of Changes
Other Study ID Numbers: 5176
First Submitted: June 30, 2006
First Posted: July 4, 2006
Last Update Posted: June 1, 2007
Last Verified: May 2007

Additional relevant MeSH terms:
Bimatoprost
Travoprost
Antihypertensive Agents